Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07083505 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

Name: A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer — clinical trial record (NCT07083505)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorCSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Started2025-08-15

View on ClinicalTrials.gov ↗

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

42 trials monitored

See 1 trial at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This is a randomized, open-label, multicenter Phase II clinical trial evaluating the efficacy and safety of HB1801 compared with Taxotere® in patients with advanced breast cancer. A total of 60 subjects with advanced breast cancer are planned to be enrolled.The trial consists of three phases: screening period, open-label treatment period, and follow-up period. HB1801 is Docetaxel for injection (Albumin-bound).

Trial Details

NCT Number	NCT07083505
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	Advanced Breast Cancer
Enrollment	60 participants
Start Date	2025-08-15
Primary Completion	2026-10-11 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-07-24